Literature DB >> 28839692

The future developments in inflammatory bowel disease care.

Peter Irving.   

Abstract

Inflammatory bowel disease (IBD) care has evolved markedly in the last decade and recent innovations in both therapeutics and service development should drive further improvements in the coming years. However, the challenges of the global economic downturn combined with more local issues, such as the reform of the National Health Service, will impact upon IBD service provision in the United Kingdom. Marrying the seemingly conflicting goals of ensuring that IBD care is provided by IBD specialists with the drive towards community-based care will require imaginative solutions. Fortunately, improvements in communication and other technologies should help in this regard.

Entities:  

Year:  2012        PMID: 28839692      PMCID: PMC5551945          DOI: 10.1136/flgastro-2011-100072

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  21 in total

Review 1.  Optimization of conventional therapy in patients with IBD.

Authors:  Kirstin M Taylor; Peter M Irving
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-04       Impact factor: 46.802

2.  E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach.

Authors:  Margarita Elkjaer; Mary Shuhaibar; Johan Burisch; Yvonne Bailey; Hanne Scherfig; Birgit Laugesen; Søren Avnstrøm; Ebbe Langholz; Colm O'Morain; Elsebeth Lynge; Pia Munkholm
Journal:  Gut       Date:  2010-12       Impact factor: 23.059

3.  A new rapid home test for faecal calprotectin in ulcerative colitis.

Authors:  M Elkjaer; J Burisch; V Voxen Hansen; B Deibjerg Kristensen; J-K Slott Jensen; P Munkholm
Journal:  Aliment Pharmacol Ther       Date:  2009-10-10       Impact factor: 8.171

4.  Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial.

Authors:  A Robinson; D G Thompson; D Wilkin; C Roberts
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

5.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

6.  Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease.

Authors:  S Kugathasan; L J Saubermann; L Smith; D Kou; J Itoh; D G Binion; A D Levine; R S Blumberg; C Fiocchi
Journal:  Gut       Date:  2007-08-06       Impact factor: 23.059

7.  Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.

Authors:  Jaya Punati; James Markowitz; Trudy Lerer; Jeffrey Hyams; Subra Kugathasan; Anne Griffiths; Anthony Otley; Joel Rosh; Marian Pfefferkorn; David Mack; Jonathan Evans; Athos Bousvaros; M Susan Moyer; Robert Wyllie; Maria Oliva-Hemker; Adam Mezoff; Neal Leleiko; David Keljo; Wallace Crandall
Journal:  Inflamm Bowel Dis       Date:  2008-07       Impact factor: 5.325

8.  Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis.

Authors:  James C Lee; Paul A Lyons; Eoin F McKinney; John M Sowerby; Edward J Carr; Francesca Bredin; Hannah M Rickman; Huzefa Ratlamwala; Alexander Hatton; Tim F Rayner; Miles Parkes; Kenneth G C Smith
Journal:  J Clin Invest       Date:  2011-09-26       Impact factor: 14.808

9.  Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health.

Authors:  Laurent Peyrin-Biroulet; Alarcos Cieza; William J Sandborn; Michaela Coenen; Yehuda Chowers; Toshifumi Hibi; Nenad Kostanjsek; Gerold Stucki; Jean-Frédéric Colombel
Journal:  Gut       Date:  2011-06-05       Impact factor: 23.059

10.  Factors affecting outcomes in Crohn's disease over 15 years.

Authors:  Jacques Cosnes; Anne Bourrier; Isabelle Nion-Larmurier; Harry Sokol; Laurent Beaugerie; Philippe Seksik
Journal:  Gut       Date:  2012-03-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.